Author: Gaikwad, Satish S.; Lee, Hyun-Jeong; Kim, Ji-Ye; Choi, Kang-Seuk
Title: Expression and serological application of recombinant epitope-repeat protein carrying an immunodominant epitope of Newcastle disease virus nucleoprotein Document date: 2019_1_31
ID: tr3ageky_1
Snippet: N-and C-terminal regions of the NP serve as B-cell epitopes in host [4, 5] . In particular, C-terminal immunological region that forms alpha helical structure is permissible for modification. Thus this epitopic region can serve as negative marker if replaced with a foreign epitope [6] . For example, amino acid sequence ETQFLDLMRAVANSMR (aa 444-459) on NDV NP is an epitope, which serves as linear immunodominant epitope (IDE) and can be replaced or.....
Document: N-and C-terminal regions of the NP serve as B-cell epitopes in host [4, 5] . In particular, C-terminal immunological region that forms alpha helical structure is permissible for modification. Thus this epitopic region can serve as negative marker if replaced with a foreign epitope [6] . For example, amino acid sequence ETQFLDLMRAVANSMR (aa 444-459) on NDV NP is an epitope, which serves as linear immunodominant epitope (IDE) and can be replaced or deleted [4] . This antigen should facilitate differentiation of vaccinated animal to that of infected during serosurveillance in the case of the marker vaccine applying vaccination program. A multiepitope protein as a vaccine candidate [7] [8] [9] [10] [11] [12] or as diagnostic reagent [13] [14] [15] has been explored in multiple instances. Multiepitope recombinant proteins are advantageous as they can be designed rationally and offers higher specificity and sensitivity [16] .
Search related documents:
Co phrase search for related documents- alpha helical structure and amino acid sequence: 1
- alpha helical structure and helical structure: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
- amino acid and foreign epitope: 1
- amino acid and helical structure: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
- amino acid and high specificity: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23
- amino acid and immunodominant epitope: 1, 2, 3, 4
- amino acid and marker vaccine: 1, 2
- amino acid and rationally design: 1, 2, 3, 4, 5
- amino acid and recombinant protein: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73
- amino acid and sensitivity high specificity: 1, 2, 3, 4, 5, 6, 7
- amino acid and vaccination program: 1, 2, 3
- amino acid and vaccine candidate: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39
- amino acid sequence and helical structure: 1, 2, 3, 4
- amino acid sequence and high specificity: 1, 2, 3
- amino acid sequence and immunodominant epitope: 1
- amino acid sequence and recombinant protein: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24
- amino acid sequence and vaccination program: 1
- amino acid sequence and vaccine candidate: 1, 2, 3, 4, 5, 6
Co phrase search for related documents, hyperlinks ordered by date